Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary

Overview

Journal Tuberc Respir Dis (Seoul)

Specialty Pulmonary Medicine

Date 2018 Jun 22

PMID 29926554

Citations 32

Authors

Yong Bum Park

Chin Kook Rhee

Hyoung Kyu Yoon

Yeon Mok Oh

Seong Yong Lim

Jin Hwa Lee

Kwang Ha Yoo

Joong Hyun Ahn

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) results in high morbidity and mortality among patients nationally and globally. The Korean clinical practice guideline for COPD was revised in 2018. The guideline was drafted by the members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Health Insurance Review and Assessment Service, Korean Physicians' Association, and Korea Respiration Trouble Association. The revised guideline encompasses a wide range of topics, including the epidemiology, diagnosis, assessment, monitoring, management, exacerbation, and comorbidities of COPD in Korea. We performed systematic reviews assisted by an expert in meta-analysis to draft a guideline on COPD management. We expect this guideline to facilitate the treatment of patients with respiratory conditions by physicians as well other health care professionals and government personnel in South Korea.

Citing Articles

Changes in muscle-to-fat ratio are associated with lung function decline and airflow obstruction in the general population.

Kim E, Leem A, Jung J, Kim Y, Park Y Respir Res. 2024; 25(1):444.

PMID: 39725996 PMC: 11673890. DOI: 10.1186/s12931-024-03081-w.

Prospective proof-of-concept observational RESEarch about traditional herbal preparation Treatment for Chronic Obstructive Pulmonary Disease (RESET-COPD-1).

Park D, Leem J, Lee B, Kim K, Jung H Front Pharmacol. 2024; 15:1437253.

PMID: 39391690 PMC: 11464318. DOI: 10.3389/fphar.2024.1437253.

Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings.

Park H, Lee J, Jeon S, Lee H, Kim B, Chae Y PLoS One. 2024; 19(6):e0304362.

PMID: 38857214 PMC: 11164367. DOI: 10.1371/journal.pone.0304362.

Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Infection in Chronic Airway Disease: A Nationwide Population-Based Study.

Yoon E, Lee H, Yoon H Tuberc Respir Dis (Seoul). 2024; 87(4):473-482.

PMID: 38835294 PMC: 11468439. DOI: 10.4046/trd.2024.0038.

Respiratory pathogen and clinical features of hospitalized patients in acute exacerbation of chronic obstructive pulmonary disease after COVID 19 pandemic.

Kim S, Kim T, Choi H, Shin T, Kim H, Jang S Sci Rep. 2024; 14(1):10462.

PMID: 38714885 PMC: 11076476. DOI: 10.1038/s41598-024-61360-4.

References

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

Parappil A, Depczynski B, Collett P, Marks G . Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology. 2010; 15(6):918-22. DOI: 10.1111/j.1440-1843.2010.01781.x. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Wedzicha J, Seemungal T . COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589):786-96. PMC: 7134993. DOI: 10.1016/S0140-6736(07)61382-8. View

Lamprecht B, McBurnie M, Vollmer W, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E . COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2010; 139(4):752-763. PMC: 3168866. DOI: 10.1378/chest.10-1253. View

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Chapman K, Beeh K, Beier J, Bateman E, DUrzo A, Nutbrown R . A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014; 14:4. PMC: 3907130. DOI: 10.1186/1471-2466-14-4. View

DUrzo A, Kerwin E, Overend T, DAndrea P, Chen H, Goyal P . Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2013; 30(3):493-508. DOI: 10.1185/03007995.2013.858618. View

Barnes P, Shapiro S, Pauwels R . Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22(4):672-88. DOI: 10.1183/09031936.03.00040703. View

10.

Kesten S, Casaburi R, Kukafka D, Cooper C . Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008; 3(1):127-36. PMC: 2528216. DOI: 10.2147/copd.s2389. View

11.

Decramer M, Chapman K, Dahl R, Frith P, Devouassoux G, Fritscher C . Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2014; 1(7):524-33. DOI: 10.1016/S2213-2600(13)70158-9. View

12.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

13.

Hwang Y, Park Y, Yoo K . Recent Trends in the Prevalence of Chronic Obstructive Pulmonary Disease in Korea. Tuberc Respir Dis (Seoul). 2017; 80(3):226-229. PMC: 5526948. DOI: 10.4046/trd.2017.80.3.226. View

14.

Barnes P, Celli B . Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5):1165-85. DOI: 10.1183/09031936.00128008. View

15.

OBrien C, Guest P, Hill S, Stockley R . Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000; 55(8):635-42. PMC: 1745831. DOI: 10.1136/thorax.55.8.635. View

16.

Chong J, Leung B, Poole P . Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 9:CD002309. PMC: 6483682. DOI: 10.1002/14651858.CD002309.pub5. View

17.

Soriano J, Rodriguez-Roisin R . Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc. 2011; 8(4):363-7. DOI: 10.1513/pats.201102-017RM. View

18.

Sciurba F, Ernst A, Herth F, Strange C, Criner G, Marquette C . A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010; 363(13):1233-44. DOI: 10.1056/NEJMoa0900928. View

19.

Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R . Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; 374(23):2222-34. DOI: 10.1056/NEJMoa1516385. View

20.

Hanania N, Mullerova H, Locantore N, Vestbo J, Watkins M, Wouters E . Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2010; 183(5):604-11. DOI: 10.1164/rccm.201003-0472OC. View